Outlook Therapeutics, Inc. (OTLK) Stock Profile — Insider Trades & Financials

Revenue$1.5M

Net Income-$23.1M

EPS$-0.38

Gross Margin-82.2%

Market Cap$20.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Robert Jahr

CEO & Executive Director

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Founded: 2010
Employees: 17
Headquarters: Iselin, New Jersey, United States

⚡

Core Efficiency

ROE?

59.81%

ROA?

-126.43%

D/E Ratio?

-1.47

Op. Margin?

-895.75%

📊

Profitability Ratios

Net Margin?

-1531.77%

Loading company sections...

Outlook Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness